Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting
18 studies found for:    Open Studies | spectrum pharmaceuticals
Show Display Options
Rank Status Study
1 Recruiting To Evaluate the Safety and Pharmacokinetics of Belinostat in Patients Who Have Wild-type, Heterozygous, and Homozygous UGT1A1*28 Genotypes
Conditions: Solid Tumors;   Hematological Malignancies
Interventions: Drug: Belinostat IV;   Drug: Belinostat
2 Recruiting To Evaluate Safety and Pharmacokinetics of Belinostat in Patients Who Have Mild, Moderate and Severe Renal Impairment.
Condition: Relapsed/Refractory Solid Tumors/Hematological Malignancies
Intervention: Drug: Belinostat
3 Recruiting Study of Poziotinib in Patients With HER2-Positive Metastatic Breast Cancer
Condition: Breast Cancer
Intervention: Drug: Poziotinib
4 Recruiting RAnDomized Trial of SPI-2012 Versus Pegfilgrastim in the Management of Chemotherapy Induced Neutropenia in Breast CANCEr Patients Receiving Docetaxel and Cyclophosphamide
Conditions: Neutropenia;   Breast Cancer
Interventions: Drug: SPI-2012;   Drug: Pegfilgrastim
5 Recruiting A Dose-Finding Study of Folotyn® (Pralatrexate Injection) Plus CHOP With Peripheral T-Cell Lymphoma (PTCL)
Condition: Peripheral T-Cell Lymphoma (PTCL)
Intervention: Drug: Pralatrexate Injection
6 Recruiting Phase 2, Single Arm, Open Label Study of Folotyn in Combination With Oral Leucovorin to Prevent or Reduce Mucositis in Patients With PTCL
Conditions: Relapsed Peripheral T-Cell Lymphoma;   Refractory Peripheral T-Cell Lymphoma
Interventions: Drug: Folotyn and Leucovorin;   Drug: Folic Acid;   Drug: Vitamin B12
7 Recruiting Zevalin Post-marketing Surveillance in Japan
Condition: Non-Hodgkin's Lymphoma (NHL)
Intervention: Drug: [90]Y-ibritumomab tiuxetan (Zevalin, BAY86-5128)
8 Recruiting Re-Induction Therapy for Relapsed Pediatric T-Cell Acute Lymphoblastic Leukemia or Lymphoma
Conditions: Acute Lymphoblastic Leukemia;   Lymphoma, Non-Hodgkin's;   Leukemia, T-Cell;   Leukemia, B-Cell
Interventions: Drug: Dexamethasone;   Drug: Panobinostat;   Drug: Liposomal vincristine;   Drug: Mitoxantrone;   Drug: Peg-asparaginase;   Drug: Bortezomib;   Drug: Intrathecal Triples;   Drug: High-dose methotrexate;   Drug: 6-Mercaptopurine;   Drug: High-dose cytarabine;   Drug: Nelarabine;   Drug: Cyclophosphamide;   Drug: Etoposide;   Drug: Clofarabine
9 Recruiting Study of Captisol Enabled Melphalan and Pharmacokinetics for Patients With Multiple Myeloma or Light Chain Amyloidosis That Are Receiving an Autologous Transplant.
Conditions: Multiple Myeloma;   Amyloidosis
Interventions: Device: Melphalan;   Drug: Pegfilgrastim;   Procedure: Autologous Hematopoietic Progenitor Cell Transplant
10 Recruiting Vincristine Sulfate Liposome Injection (Marqibo®) in Combination With UK ALL R3 Induction Chemotherapy for Children, Adolescents, and Young Adults With Relapsed ALL
Conditions: ALL, Childhood;   Lymphoblastic Leukemia, Acute, Childhood;   Lymphoblastic Leukemia, Acute
Intervention: Drug: Marqibo in combination with UK ALL R3
11 Recruiting Vincristine Sulfate Liposome in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia
Condition: Recurrent Adult Acute Myeloid Leukemia
Interventions: Drug: Vincristine Sulfate Liposome;   Other: Laboratory Biomarker Analysis
12 Not yet recruiting Vincristine Sulfate Liposome Injection (Marqibo®), Bendamustine and Rituximab—Phase I Trial in Indolent B-cell Lymphoma
Conditions: Lymphoma, Non-Hodgkin;   Lymphoma, Follicular;   Lymphoma, Mantle-Cell;   Lymphoma, Small-Cell;   Waldenstrom Macroglobulinemia;   Lymphoma, B-Cell, Marginal Zone
Interventions: Drug: Rituximab;   Drug: Bendamustine;   Drug: Vincristine sulfate liposome injection
13 Recruiting MRSI to Predict Response to RT/TMZ ± Belinostat in GBM
Condition: Glioblastoma Multiforme of Brain
Interventions: Radiation: Standard Radiation Therapy;   Drug: Standard Temozolomide;   Drug: Belinostat
14 Recruiting Zevalin Before Stem Cell Transplant in Treating Patients With Non-Hodgkin Lymphoma
Conditions: Refractory Non Hodgkin Lymphoma;   Relapsed Non Hodgkin Lymphoma
Interventions: Biological: rituximab;   Biological: ibritumomab tiuxetan;   Biological: anti-thymocyte globulin;   Radiation: total nodal irradiation;   Procedure: peripheral blood stem cell transplantation;   Procedure: allogeneic hematopoietic stem cell transplantation;   Drug: cyclosporine;   Drug: mycophenolate mofetil
15 Recruiting Hyper-CVAD With Liposomal Vincristine in Acute Lymphoblastic Leukemia
Condition: Leukemia
Interventions: Drug: Rituximab;   Drug: Imatinib;   Drug: Cyclophosphamide;   Drug: Doxorubicin;   Drug: Mesna;   Drug: VSLI;   Drug: Solu-Medrol;   Drug: Methotrexate;   Drug: Ara-C;   Drug: G-CSF;   Drug: Pegfilgrastim;   Drug: Dexamethasone
16 Not yet recruiting Efficacy of Vasculera in Prevention on Post-op Pain and Edema Following Lower Extremity Venous Treatment in the Outpatient Setting
Conditions: Venous Insufficiency of Leg;   Venous Reflux;   Varicose Veins;   Lower Extremity Edema Chronic
Interventions: Other: Vasculera;   Other: Placebo
17 Recruiting Behavioral Treatment of Adolescent Substance Use
Condition: Substance Use Disorders
Interventions: Behavioral: Behavior Therapy;   Behavioral: Working Memory Training
18 Recruiting Pheno- & Genotyping POF (WHO III)
Conditions: Premature Ovarian Failure (POF);   Incipient Ovarian Failure;   Poor Response After Ovarian Hyperstimulation;   Early Menopause;   Hypergonadotropic Amenorrhea

Indicates status has not been verified in more than two years